Angiotensin receptor blocker improves coronary flow velocity reserve in hypertensive patients: Comparison with calcium channel blocker

Hypertension Research

Volumn 30, Issue 8, 2007, Pages 699-706

  Kamezaki, Fumihiko ^a   Tasaki, Hiromi ^a   Yamashita, Kazuhito ^a   Shibata, Kiyoko ^a   Hirakawa, Noriko ^a   Tsutsui, Masato ^a   Kouzuma, Ryouji ^a   Nagatomo, Toshihisa ^a   Adachi, Tetsuo ^b   Otsuji, Yutaka ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Angiotensin receptor blocker; Calcium channel blocker; Coronary flow velocity reserve; Transthoracic Doppler echocardiography

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; NIFEDIPINE; VALSARTAN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERTENSION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; PREDICTION; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD FLOW VELOCITY; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CORONARY CIRCULATION; ECHOCARDIOGRAPHY; FEMALE; HUMANS; HYPEREMIA; HYPERTENSION; MALE; MIDDLE AGED; NIFEDIPINE; TETRAZOLES; VALINE;

EID: 34948847629     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.30.699     Document Type: Article

References (37)

1. Kjeldsen SE, Julius S, Mancia G, et al: Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens 2006; 24: 1405-1412.
2. Cohn JN, Tognoni G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-1675.
3. Pfeffer MA, McMurray JJ, Velazquez EJ, et al, Valsartan in Acute Myocardial Infarction Trial Investigators: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-1906.
4. Brenner BM, Cooper ME, de Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
5. Lithell H, Hansson L, Skoog I, et al: The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875-886.
6. Yokoyama I, Ohtake T, Momomura S, Nishikawa J, Sasaki Y, Omata M: Reduced coronary flow reserve in hypercholesterolemic patients without overt coronary stenosis. Circulation 1996; 94: 3232-3238.
7. Pitkanen OP, Nuutila P, Raitakari OT, et al: Coronary flow reserve is reduced in young men with NIDDM. Diabetes 1998; 47: 248-254.
8. Schachinger V, Britten MB, Zeiher AM: Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-1906.
9. Suwaidi J, Hamasaki S, Higano ST, Nishimura RA, Holmes DR, Lerman A: Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 948-954.
10. Hozumi T, Yoshida K, Ogata Y, et al: Noninvasive assessment of significant left anterior descending coronary artery stenosis by coronary flow velocity reserve using transthoracic color Doppler echocardiography. Circulation 1998; 97: 1557-1562.
11. Hozumi T, Yoshida K, Akasaka T, et al: Noninvasive assessment of coronary flow velocity and coronary flow velocity reserve in the left anterior descending coronary artery by Doppler echocardiography: comparison with invasive technique. J Am Coll Cardiol 1998; 32: 1251-1259.
12. Kobayashi K, Yamashita K, Tasaki H, et al: Evaluation of improved coronary flow velocity reserve using transthoracic Doppler echocardiography after single LDL apheresis. Ther Apher Dial 2004; 8; 383-389.
13. Yamashita K, Tasaki H, Nagai Y, et al: Experimental hyperhomocysteinemia impairs coronary flow velocity reserve. Int J Cardiol 2005; 104; 163-169.
14. Lupi A, Buffon A, Finocchiaro ML, Conti E, Maseri A, Crea F: Mechanisms of adenosine-induced epicardial coronary artery dilatation. Eur Heart J 1997; 18: 614-617.
15. Leipert B, Becker BF, Gerlach E: Different endothelial mechanisms involved in coronary responses to known vasodilators. Am J Physiol 1992; 262: H1676-H1683.
16. Fusejima K: Noninvasive measurement of coronary artery blood flow using combined two-dimensional and Doppler echocardiography. J Am Coll Cardiol 1987; 10: 1024-1031.
17. Ross JJ Jr, Mintz RG, Chandrasekaran K: Transthoracic two-dimensional high frequency (7.5 MHz) ultrasonic visualization of the distal left anterior coronary artery. J Am Coll Cardiol 1990; 15: 373-377.
18. Dayanikli F, Grambow D, Muzik O, Mosca L, Rubenfire M, Schweiger M: Early detection of abnormal coronary flow reserve in asymptomatic men at high risk for coronary artery disease using positron emission tomography. Circulation 1994; 90: 808-817.
19. Diamond JA, Phillips RA: Hypertensive heart disease. Hypertens Res 2005; 28: 191-202.
20. Rizzoni D, Porteri E, Boari GEM, et al: Prognostic significance of small-artery structure in hypertension. Circulation 2003; 108: 2230-2235.
21. Treasure CB, Klein JL, Vista JA, et al: Hypertension and left ventricular hypertrophy are associated with impaired endothelial-mediated relaxation in human coronary resistance vessels. Circulation 1993; 87: 86-93.
22. Antony I, Nitenberg A, Foult J-M, Aptecar E: Coronary vasodilator reserve in untreated and treated hypertensive patients with and without left ventricular hypertrophy. J Am Coll Cardiol 1993; 22: 514-520.
23. Brush JE, Faxon DP, Salmon S, Jakobs AK, Ryan TJ: Abnormal endothelium-dependent coronary vasomotion in hypertensive patients. J Am Coll Cardiol 1992; 19: 809-815.
24. Egashira K, Suzuki S, Hirooka Y, et al: Impaired endothelium-dependent vasodilation of large epicardial and resistance coronary arteries in patients with essential hypertension. Hypertension 1995; 25: 201-206.
25. Park JB, Schiffrin EL: Small artery remodeling is the most prevalent (earliest?) form of target organ damage in mild essential hypertension. J Hypertens 2001; 19: 921-930.
26. Nickenig G, Harrison DG: The AT1-type angiotensin receptor in oxidative stress and atherogenisis. part 1: oxidative stress and atherogenesis. Circulation 2002; 105: 393-396.
27. Fliser D, Buchholz K, Haller H, the European Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators: Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 110: 1103-1107.
28. Suzuki S, Ohtsuka S, Ishikawa K, Yamaguchi I: Effects of nicardipine on coronary, vertebral and renal arterial flows in patients with essential hypertension. Hypertens Res 2003; 26: 193-199.
29. Schiffrin EL, Touyz RM: From bedside to bench bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension. Am J Physiol Heart Circ Physiol 2004; 287: H435-H446.
30. Takemoto M, Egashira K, Tomita H, et al: Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis. Hypertension 1997; 30: 1621-1627.
31. Okazaki H, Minamino T, Tsukamoto O, et al: Angiotensin II type 1 receptor blocker prevents atrial structural remodeling in rats with hypertension and induced by chronic nitric oxide inhibition. Hypertens Res 2006; 29: 277-284.
32. Schiffrin EL, Park JB, Intengan HD, Touyz; RM: Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000; 101: 1653-1659.
33. Rizzoni D, Palombo C, Porteri E, et al: Relationships between coronary flow vasodilator capacity and small artery remodeling in hypertensive patients. J Hypertens 2003; 108: 625-631.
34. Sun H, Mohri M, Shimokawa H, Usui M, Urakami L, Takeshita A: Coronary microvascular spasm causes myocardial ischemia in patients with vasospastic angina. J Am Coll Cardiol 2002; 39: 847-851.
35. Neri Serneri GG, Boddi M, Modesti PA, et al: Cardiac angiotensin II participates in coronary microvessel inflammation of unstable angina and strengthens the immunomediated component. Circ Res 2004; 94: 1630-1637.
36. 1) receptors decreased myocardial microvessel density after experimental myocardial infarction. Cardiovasc Res 2003; 57: 434-442.
37. Suzuki H, Kanno Y: Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients. Hypertens Res 2005; 28: 307-314.